CELLINK, the creator of one of the world's first universal Bioinks, has carried out a directed share issue of 756,676 shares of series B at a subscription price of SEK 132.5 per share. The subscription price has been determined through an accelerated bookbuilding procedure.

 

The directed share issue will provide CELLINK with gross proceeds of approximately SEK 100 million.

 

Carnegie acted as Sole Bookrunner and Lead Manager in connection with the transaction. Baker McKenzie is legal advisor to Carnegie. The Baker McKenzie team mainly consists of partner Joakim Falkner with support from Henric Roth and Ian Gulam.

Explore Our Newsroom
See All News